Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Development and validation of HPLC method for determination of indomethacin and its two degradation products in topical gel

Nováková L, Matysová L, Havlíková L, Solich P.

Jazyk angličtina Země Velká Británie

Typ dokumentu validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc07520422

Indomethacin forms by decomposition two degradation products: 4-chlorobenzoic acid and 5-methoxy-2-methylindoleacetic acid. They have to be monitored together with an active substance both during manufacturing process and storage of pharmaceuticals. European Pharmacopoeia (Ph. Eur. 4) describes titration method for determination of indomethacin, which is not very convenient in this case for practical use. Therefore, high performance liquid chromatography is the method-of-choice enabling determination of active substance and its degradation products during one-step procedure simultaneously and automatically. We have developed a fast, simple and fully automated analytical method for determination of indomethacin and its two impurities in pharmaceutical preparation using HPLC with UV detection. Various stationary phases were tested, especially new types of Zorbax columns made by Agilent. While the conventional C18 stationary phases were not convenient enough to achieve quick and reliable separation, Zorbax-Phenyl analytical column (75 mm x 4.6 mm, 3.5 microm) enables separation of indomethacin and its two degradation products during 7.5 min. Chromatography was performed using isocratic elution with binary mobile phase composed of acetonitrile and 0.2% phosphoric acid (50:50, v/v) at flow rate 0.6 ml/min. Even faster separation of standards was obtained with analytical column Zorbax SB-CN (150 mm x 4.6 mm, 5 microm). The separation was effected with mobile phase of the same composition, only the flow rate was increased to 1.2 ml/min. The analytical run was shortened to 5 min. Both methods use detection wavelength 237 nm and both can use either ketoprofen or flurbiprofen as internal standard for quantitation. The first method was finally chosen for validation because of the occurrence of placebo interferences in the case of using Zorbax SB-CN. System suitability parameters and validation parameters including method precision, accuracy, linearity, selectivity and robustness were set up. Afterwards, the method was successfully applied for the practical determination of indomethacin and its degradation products in a topical gel and for compound degradation control during stability studies.

Citace poskytuje Crossref.org

000      
00000naa 2200000 a 4500
001      
bmc07520422
003      
CZ-PrNML
005      
20111210131122.0
008      
090401s2005 xxk e eng||
009      
AR
024    __
$a 10.1016/j.jpba.2004.09.012 $2 doi
035    __
$a (PubMed)15862664
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Nováková, Lucie, $d 1979- $7 xx0048951
245    10
$a Development and validation of HPLC method for determination of indomethacin and its two degradation products in topical gel / $c Nováková L, Matysová L, Havlíková L, Solich P.
314    __
$a Department of Analytical Chemistry, Faculty of Pharmacy, Charles University, Heyrovského 1203, 50005 Hradec Králové, Czech Republic
520    9_
$a Indomethacin forms by decomposition two degradation products: 4-chlorobenzoic acid and 5-methoxy-2-methylindoleacetic acid. They have to be monitored together with an active substance both during manufacturing process and storage of pharmaceuticals. European Pharmacopoeia (Ph. Eur. 4) describes titration method for determination of indomethacin, which is not very convenient in this case for practical use. Therefore, high performance liquid chromatography is the method-of-choice enabling determination of active substance and its degradation products during one-step procedure simultaneously and automatically. We have developed a fast, simple and fully automated analytical method for determination of indomethacin and its two impurities in pharmaceutical preparation using HPLC with UV detection. Various stationary phases were tested, especially new types of Zorbax columns made by Agilent. While the conventional C18 stationary phases were not convenient enough to achieve quick and reliable separation, Zorbax-Phenyl analytical column (75 mm x 4.6 mm, 3.5 microm) enables separation of indomethacin and its two degradation products during 7.5 min. Chromatography was performed using isocratic elution with binary mobile phase composed of acetonitrile and 0.2% phosphoric acid (50:50, v/v) at flow rate 0.6 ml/min. Even faster separation of standards was obtained with analytical column Zorbax SB-CN (150 mm x 4.6 mm, 5 microm). The separation was effected with mobile phase of the same composition, only the flow rate was increased to 1.2 ml/min. The analytical run was shortened to 5 min. Both methods use detection wavelength 237 nm and both can use either ketoprofen or flurbiprofen as internal standard for quantitation. The first method was finally chosen for validation because of the occurrence of placebo interferences in the case of using Zorbax SB-CN. System suitability parameters and validation parameters including method precision, accuracy, linearity, selectivity and robustness were set up. Afterwards, the method was successfully applied for the practical determination of indomethacin and its degradation products in a topical gel and for compound degradation control during stability studies.
650    _2
$a aplikace lokální $7 D000287
650    _2
$a vysokoúčinná kapalinová chromatografie $x metody $x normy $7 D002851
650    _2
$a gely $x analýza $x aplikace a dávkování $x metabolismus $7 D005782
650    _2
$a indomethacin $x analýza $x aplikace a dávkování $x metabolismus $7 D007213
650    _2
$a financování organizované $7 D005381
655    _2
$a validační studie $7 D023361
700    1_
$a Matysová, Ludmila, $d 1967- $7 stk2007393930
700    1_
$a Chocholoušová Havlíková, Lucie $7 stk2007393934
700    1_
$a Solich, Petr, $d 1955- $7 jo2007285395
773    0_
$w MED00002894 $t Journal of pharmaceutical and biomedical analysis $g Roč. 37, č. 5 (2005), s. 899-905 $x 0731-7085
910    __
$a ABA008 $b x $y 9
990    __
$a 20090310084605 $b ABA008
991    __
$a 20090716094156 $b ABA008
999    __
$a ok $b bmc $g 638225 $s 491024
BAS    __
$a 3
BMC    __
$a 2005 $b 37 $c 5 $d 899-905 $i 0731-7085 $m Journal of pharmaceutical and biomedical analysis $x MED00002894
LZP    __
$a 2009-B2/ipme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...